The ezetimibe controversy: implications for clinical practice.

Khanderia, Ujjaini; Regal, Randolph E; Rubenfire, Melvyn; Boyden, Thomas

Khanderia, Ujjaini; Regal, Randolph E; Rubenfire, Melvyn; Boyden, Thomas.

Affiliation

Khanderia U; College of Pharmacy and Department of Pharmacy Services, University of Michigan, Ann Arbor, Michigan 48109-5008, USA. shamo@med.umich.edu

Ther Adv Cardiovasc Dis ; 5(4): 199-208, 2011 Aug.

Article in En | MEDLINE | ID: mdl-21636623

Subject(s)

Anticholesteremic Agents/therapeutic use; Azetidines/therapeutic use; Cholesterol, LDL/drug effects; Acute Coronary Syndrome/drug therapy; Acute Coronary Syndrome/physiopathology; Anticholesteremic Agents/adverse effects; Azetidines/adverse effects; Cardiovascular Diseases/etiology; Cardiovascular Diseases/prevention & control; Cholesterol, LDL/blood; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Neoplasms/chemically induced; Neoplasms/etiology; Plaque, Atherosclerotic/drug therapy; Plaque, Atherosclerotic/pathology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azetidines / Cholesterol, LDL / Anticholesteremic Agents Type of study: Clinical_trials / Etiology_studies Limits: Humans Language: En Journal: Ther Adv Cardiovasc Dis Journal subject: ANGIOLOGIA / CARDIOLOGIA / TERAPEUTICA Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google